Menu
Back to User profile » Prof. Dr. Wenfeng Fang
Papers published by Prof. Dr. Wenfeng Fang:
HER2 Amplification in Advanced NSCLC Patients After Progression on EGFR-TKI and Clinical Response to EGFR-TKI Plus Pyrotinib Combination Therapy
Gan J, Huang Y, Liao J, Pang L, Fang W
OncoTargets and Therapy 2021, 14:5297-5307
Published Date: 18 November 2021
Impact of gefitinib in early stage treatment on circulating cytokines and lymphocytes for patients with advanced non–small cell lung cancer
Sheng J, Fang W, Liu X, Xing S, Zhan J, Ma Y, Huang Y, Zhou N, Zhao H, Zhang L
OncoTargets and Therapy 2017, 10:1101-1110
Published Date: 21 February 2017
The efficacy and safety of nivolumab in previously treated advanced non-small-cell lung cancer: a meta-analysis of prospective clinical trials
Huang J, Zhang Y, Sheng J, Zhang H, Fang W, Zhan J, Zhou T, Chen Y, Liu L, Zhang L
OncoTargets and Therapy 2016, 9:5867-5874
Published Date: 23 September 2016
Consolidation chemotherapy improves progression-free survival in stage III small-cell lung cancer following concurrent chemoradiotherapy: a retrospective study
Chen XR, Liang JZ, Ma SX, Fang WF, Zhou NN, Liao H, Li DL, Chen LK
OncoTargets and Therapy 2016, 9:5729-5736
Published Date: 19 September 2016
In vitro and in vivo efficacy of afatinib as a single agent or in combination with gemcitabine for the treatment of nasopharyngeal carcinoma
Xue C, Tian Y, Zhang J, Zhao YY, Zhan JH, Fang WF, Zhang L
Drug Design, Development and Therapy 2016, 10:1299-1306
Published Date: 31 March 2016
Efficacy of BIBF 1120 or BIBF 1120 plus chemotherapy on nasopharyngeal carcinoma in vitro and in vivo
Xue C, Tian Y, Zhang J, Zhao Y, Zhan J, Fang W, Zhang L
Drug Design, Development and Therapy 2016, 10:1173-1180
Published Date: 15 March 2016
Clinical analysis of 50 Eastern Asian patients with primary pulmonary large-cell neuroendocrine carcinoma
Zhang XK, Qin T, Zeng YD, Zhao YY, Hou X, Fang WF, Hong SD, Zhou T, Hu ZH, Yang YP, Ma YX, Xue C, Huang Y, Zhao HY, Zhang L
OncoTargets and Therapy 2015, 8:1219-1227
Published Date: 26 May 2015
Risk of treatment-related deaths with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a meta-analysis of 41 randomized controlled trials
Hong SD, Fang WF, Liang WH, Yan Y, Zhou T, Qin T, Wu X, Ma YX, Zhao YY, Yang YP, Hu ZH, Xue C, Hou X, Chen Y, Huang Y, Zhao HY, Zhang L
OncoTargets and Therapy 2014, 7:1851-1867
Published Date: 7 October 2014
Serum proteomic study on EGFR-TKIs target treatment for patients with NSCLC
Wu X, Liang WH, Hou X, Lin Z, Zhao HY, Huang Y, Fang WF, Zhao YY, Wu JX, Yang YP, Xue C, Hu ZH, Zhang J, Zhang JW, Ma YX, Zhou T, Qin T, Zhang L
OncoTargets and Therapy 2013, 6:1481-1491
Published Date: 21 October 2013